A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers

Trial Profile

A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2014

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2014 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 23 Jan 2014 According to ClinicalTrials.gov record, Planned initiation date changed from 1 Dec 2013 to 1 May 2014.
    • 23 Jan 2013 Status changed from not yet recruiting to discontinued, based on information in Novartis' Form 20-F (http://www.sec.gov/Archives/edgar/data/1114448/000104746913000377/a2212460z20-f.htm).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top